Fortrea Q2 revenue beats expectations, outlook raised
Fortrea Q2 revenue beats expectations, outlook raised
Overview
US contract research firm's Q2 revenue declined yr/yr but beat analyst expectations
Adjusted EBITDA for Q2 beat analyst expectations
Company raised full-year 2026 revenue and adjusted EBITDA guidance
Outlook
Fortrea raises full-year 2026 revenue guidance to $2,620 mln-$2,690 mln
Company expects full-year 2026 adjusted EBITDA of $205 mln-$220 mln
Fortrea says focus remains on commercial execution and margin expansion for sustainable growth
Result Drivers
COMMERCIAL EXECUTION - Co said results reflect continued progress against its strategy and disciplined execution across the business, per CEO Anshul Thakral
SUSTAINED DEMAND - Book-to-bill ratio above 1.0x for fourth consecutive qtr, indicating ongoing contract wins, per CEO Anshul Thakral
Company press release: ID:nGNX2mTJLn
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $678.20 mln | $647.46 mln (11 Analysts) |
Q2 Loss Per Share |
| $0.14 |
|
Q2 Net Loss |
| $13.20 mln |
|
Q2 Adjusted EBITDA | Beat | $58.70 mln | $48.69 mln (10 Analysts) |
Q2 Pretax Profit | Miss | -$1.20 mln | $23.94 mln (6 Analysts) |
Q2 Operating Income |
| $14.80 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 5 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Fortrea Holdings Inc is $18.50, about 10.6% below its July 28 closing price of $20.70
The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 13 three months ago
Reuters Recommended Reads
July 28 - IQVIA raises annual profit forecast on clinical research demand
July 27 - UK's Science Group preliminary H1 core revenue falls; expects buyback to exceed £20 mln
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Fortrea Holdings
See all newsFortrea Q3 revenue beats expectations on bookings momentum, guidance raised
Brief: Fortrea And Omico Collaboration To Advance Biomarker-Led Oncology Drug Development
US RESEARCH ROUNDUP-Eli Lilly, Netflix, Zscaler
Brief: Fortrea Completes Acquisition Of The Early Phase Services Division From Worldwide Clinical Trials
US RESEARCH ROUNDUP-Acuity, Dell Technologies, Nike